Adma Biologics (ADMA) Total Current Liabilities (2011 - 2025)

Adma Biologics has reported Total Current Liabilities for 14 years, with the latest figure at $69.5 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities rose 25.2% year-over-year to $69.5 million; the trailing twelve-month figure through Dec 2025 stood at $69.5 million (up 25.2% YoY), and the FY2025 full-year result was $69.5 million, up 25.2% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $69.5 million, up from $56.5 million in the prior quarter.
• The five-year high for Total Current Liabilities was $74.9 million in Q2 2025, with the low at $18.2 million in Q2 2021.
• Historically, Total Current Liabilities has averaged $43.4 million across 5 years, with a median of $43.1 million in 2023.
• Annual changes were most pronounced in 2021 — Total Current Liabilities jumped 96.3% — and 2023, when it decreased 5.85%.
• Adma Biologics' Total Current Liabilities stood at $30.4 million in 2021, then increased by 29.26% to $39.3 million in 2022, then advanced by 26.84% to $49.8 million in 2023, then gained by 11.52% to $55.5 million in 2024, then climbed by 25.2% to $69.5 million in 2025.
• The last three Total Current Liabilities figures came in at $69.5 million (Q4 2025), $56.5 million (Q3 2025), and $74.9 million (Q2 2025), per Business Quant data.